Pharmacists
Access pharmacist-made resources designed to support pharmacists in their everyday practice, including CPD logs and more. These tools are created to help pharmacists stay organized, track their professional development, streamline essential responsibilities, enhance accuracy, and improve patient care, making your daily workflow more efficient and effective.
Counterfeit Ozempic Pens Detected
April 2025
⚠️ Safety Alert: Counterfeit Ozempic Injection Pens Detected ⚠️
Consumers and health professionals be aware that counterfeit Ozempic-labelled pens, including those with the false batch number MPSD916, have been intercepted at the Australian border. These products pose serious health risks and have not been assessed for quality, safety, or efficacy. Though they may appear genuine, they contain packaging errors such as inconsistent text spacing and bolding.
For more information, refer to the safety alert from the Therapeutic Goods Administration:
tga.gov.au/news/safety-alerts/counterfeit-ozempic-injection-pens-detected
Semaglutide
February 2025
The TGA has approved a new indication for semaglutide.
Semaglutide has been approved as adjunct therapy to reduce the risk of major adverse cardiovascular events such as non-fatal myocardial infarction, non-fatal stroke or cardiovascular death in adults with pre-existing heart disease, a Body Mass Index ≥27kg/m2 and no history of diabetes.
The high cost of the medication, however, is currently a significant barrier to access for treatment.
References:
Australian Pharmacist 2025 (australianpharmacist.com.au/wegovy-approved-to-cut-cardiovascular-risk/)
RACGP 2025 (www1.racgp.org.au/newsgp/clinical/wegovy-approved-for-cardiovascular-disease-in-over#:~:text=The%20TGA%20has%20approved%20semaglutide%20%28sold%20as%20Wegovy%29,adverse%20cardiovascular%20events%20in%20overweight%20and%20obe)
